NASDAQ:AVDL - Avadel Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.32 +0.06 (+4.76 %) (As of 05/19/2019 04:00 PM ET)Previous Close$1.32Today's Range$1.26 - $1.3952-Week Range$1.03 - $7.97Volume191,900 shsAverage Volume238,311 shsMarket Capitalization$48.85 millionP/E RatioN/ADividend YieldN/ABeta1.69 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland. Receive AVDL News and Ratings via Email Sign-up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AVDL Previous Symbol CUSIPN/A CIK1012477 Webwww.avadel.com Phone353-1485-1200Debt Debt-to-Equity Ratio41.63 Current Ratio3.27 Quick Ratio3.13Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$103.27 million Price / Sales0.47 Cash FlowN/A Price / Cash FlowN/A Book Value($0.26) per share Price / Book-5.08Profitability EPS (Most Recent Fiscal Year)($1.99) Net Income$-95,300,000.00 Net Margins-111.19% Return on Equity-215.96% Return on Assets-31.99%Miscellaneous Employees144 Outstanding Shares37,010,000Market Cap$48.85 million Next Earnings Date8/6/2019 (Estimated) OptionableOptionable Avadel Pharmaceuticals (NASDAQ:AVDL) Frequently Asked Questions What is Avadel Pharmaceuticals' stock symbol? Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL." How will Avadel Pharmaceuticals' stock buyback program work? Avadel Pharmaceuticals announced that its board has approved a share repurchase program on Wednesday, March 28th 2018, which permits the company to repurchase $7,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 2.7% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's management believes its shares are undervalued. How were Avadel Pharmaceuticals' earnings last quarter? Avadel Pharmaceuticals PLC (NASDAQ:AVDL) issued its earnings results on Wednesday, May, 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.40) by $0.05. The business had revenue of $16.44 million for the quarter. Avadel Pharmaceuticals had a negative return on equity of 215.96% and a negative net margin of 111.19%. View Avadel Pharmaceuticals' Earnings History. When is Avadel Pharmaceuticals' next earnings date? Avadel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Avadel Pharmaceuticals. What price target have analysts set for AVDL? 4 brokerages have issued 1 year price targets for Avadel Pharmaceuticals' shares. Their predictions range from $2.00 to $10.00. On average, they expect Avadel Pharmaceuticals' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 354.5% from the stock's current price. View Analyst Price Targets for Avadel Pharmaceuticals. What is the consensus analysts' recommendation for Avadel Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Avadel Pharmaceuticals. Has Avadel Pharmaceuticals been receiving favorable news coverage? Media headlines about AVDL stock have trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Avadel Pharmaceuticals earned a daily sentiment score of 1.9 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days. Are investors shorting Avadel Pharmaceuticals? Avadel Pharmaceuticals saw a increase in short interest during the month of April. As of April 15th, there was short interest totalling 2,838,982 shares, an increase of 31.4% from the March 29th total of 2,161,146 shares. Based on an average daily trading volume, of 192,169 shares, the short-interest ratio is currently 14.8 days. Currently, 7.7% of the shares of the company are short sold. View Avadel Pharmaceuticals' Current Options Chain. Who are some of Avadel Pharmaceuticals' key competitors? Some companies that are related to Avadel Pharmaceuticals include Acer Therapeutics (ACER), Chiasma (CHMA), CELYAD SA/ADR (CYAD), Poxel (PXXLF), Ardelyx (ARDX), Aeglea Bio Therapeutics (AGLE), Nature's Sunshine Products (NATR), Northwest Biotherapeutics (NWBO), Chimerix (CMRX), Cue Biopharma (CUE), Intec Pharma (NTEC), BELLUS Health (BLUSF), BioXcel Therapeutics (BTAI), Seres Therapeutics (MCRB) and TAIWAN LIPOSOME/S (TLC). What other stocks do shareholders of Avadel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Chaarat Gold (CGH), Fossil Group (FOSL), Associated British Foods (ABF), AMC Entertainment (AMC), First Data (FDC), Ciena (CIEN), Apollo Global Management (APO) and China Unicom (Hong Kong) (CHU). Who are Avadel Pharmaceuticals' key executives? Avadel Pharmaceuticals' management team includes the folowing people: Mr. Michael F. Kanan, Sr. VP & CFO (Age 56)Mr. Phillandas T. Thompson, Sr. VP, Gen. Counsel & Corp. Sec. (Age 45)Mr. Gregory J. Divis, VP of Corp. and Bus. Devel. (Age 54)Ms. Sandra L. Hatten, Sr. VP of Quality & Regulatory Affairs (Age 62)Mr. Gregory J. Divis Jr., Interim Chief Exec. Officer (Age 52) Who are Avadel Pharmaceuticals' major shareholders? Avadel Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Brandes Investment Partners LP (19.06%), Acadian Asset Management LLC (2.28%), Morgan Stanley (1.93%), Renaissance Technologies LLC (1.78%) and Wedbush Securities Inc. (0.10%). Company insiders that own Avadel Pharmaceuticals stock include Craig R Stapleton, Greg J Divis, Guillaume Cerutti, Healthcare Master Fun Broadfin, James E Flynn, Michael S Anderson, Peter J Thornton, Phillandas T Thompson and Sandra L Hatten. View Institutional Ownership Trends for Avadel Pharmaceuticals. Which institutional investors are selling Avadel Pharmaceuticals stock? AVDL stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Brandes Investment Partners LP and Morgan Stanley. Company insiders that have sold Avadel Pharmaceuticals company stock in the last year include James E Flynn, Michael S Anderson and Sandra L Hatten. View Insider Buying and Selling for Avadel Pharmaceuticals. Which institutional investors are buying Avadel Pharmaceuticals stock? AVDL stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Wedbush Securities Inc.. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Craig R Stapleton, Greg J Divis, Michael S Anderson, Peter J Thornton, Phillandas T Thompson and Sandra L Hatten. View Insider Buying and Selling for Avadel Pharmaceuticals. How do I buy shares of Avadel Pharmaceuticals? Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Avadel Pharmaceuticals' stock price today? One share of AVDL stock can currently be purchased for approximately $1.32. How big of a company is Avadel Pharmaceuticals? Avadel Pharmaceuticals has a market capitalization of $48.85 million and generates $103.27 million in revenue each year. The company earns $-95,300,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Avadel Pharmaceuticals employs 144 workers across the globe. What is Avadel Pharmaceuticals' official website? The official website for Avadel Pharmaceuticals is http://www.avadel.com. How can I contact Avadel Pharmaceuticals? Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 353-1485-1200 or via email at [email protected] MarketBeat Community Rating for Avadel Pharmaceuticals (NASDAQ AVDL)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 225 (Vote Outperform)Underperform Votes: 211 (Vote Underperform)Total Votes: 436MarketBeat's community ratings are surveys of what our community members think about Avadel Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVDL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVDL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: What is the Stochastic Momentum Index (SMI)? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.